Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 81.3 million, a decrease of 24.2% compared to RMB 107.3 million in the same period of 2024[6]. - The net profit for the same period was RMB 27.3 million, down 26.3% from RMB 37.0 million year-on-year[6]. - The gross profit was RMB 60.1 million, reflecting a 13.6% decline compared to RMB 69.6 million in the previous year[9]. - Revenue for the six months ended June 30, 2025, was RMB 81,281,000, a decrease of 24.3% compared to RMB 107,291,000 for the same period in 2024[54]. - Gross profit for the same period was RMB 60,140,000, down 13.6% from RMB 69,618,000 in 2024[54]. - Net profit for the period was RMB 27,261,000, representing a decline of 26.3% from RMB 36,969,000 in the previous year[54]. - Basic and diluted earnings per share for the period were RMB 0.13, down from RMB 0.18 in 2024[54]. Revenue Breakdown - Revenue from consumer genetic testing services was RMB 75.9 million, down 27.3% year-on-year, while revenue from cancer screening services increased by 85.7% to RMB 5.3 million[7]. - Revenue from consumer-grade genetic testing services was RMB 75,947 thousand for the six months ended June 30, 2025, down from RMB 104,419 thousand in 2024, representing a decline of 27.2%[68]. - Revenue from cancer screening services increased by 85.7% year-over-year to RMB 5.3 million, due to an expanded product offering[17]. Cost and Expenses - Sales and distribution expenses decreased by 23.4% to RMB 10.4 million from RMB 13.6 million in the previous year, primarily due to reduced revenue[23]. - The cost of services provided was RMB 21,141 thousand for the six months ended June 30, 2025, down from RMB 37,673 thousand in 2024, reflecting a decrease of 43.8%[71]. - Research and development costs amounted to RMB 8,151 thousand for the six months ended June 30, 2025, compared to RMB 9,934 thousand in 2024, indicating a reduction of 17.9%[71]. Assets and Liabilities - Cash and cash equivalents decreased by 6.3% from RMB 490.3 million as of December 31, 2024, to RMB 459.5 million as of June 30, 2025[32]. - Total assets as of June 30, 2025, were RMB 649,869,000, slightly up from RMB 647,837,000 as of December 31, 2024[56]. - Current liabilities decreased significantly to RMB 38,151,000 from RMB 90,640,000 at the end of 2024, indicating improved liquidity[55]. - Non-current liabilities increased to RMB 38,269,000 from RMB 33,157,000, reflecting changes in financing arrangements[56]. Corporate Governance and Compliance - The company has established an audit committee to provide independent opinions on financial reporting procedures, internal controls, and risk management systems[91]. - The audit committee consists of three members, ensuring compliance with the relevant listing rules and corporate governance codes[91]. - The company has adhered to strict corporate governance principles, maintaining high standards of ethics, transparency, accountability, and integrity[89]. - The interim financial results for the six months ending June 30, 2025, have been reviewed by the audit committee[91]. - The company has confirmed compliance with the standard code for securities transactions by directors during the reporting period[90]. Future Plans and Market Potential - The penetration rate of the consumer genetic testing market in China is expected to grow from 0.8% in 2020 to 11.6% by 2030, indicating significant market potential[10]. - The company plans to enhance collaboration with industry leaders to establish industry standards and accelerate market penetration[10]. - Future product development will focus on expanding cancer screening offerings, including innovative tests for esophageal, endometrial, and bladder cancers[11]. - The company aims to increase R&D investment to develop high-cost performance tumor early screening products, contributing to public health goals[11]. - The company aims to pursue selective regional expansion and acquisition opportunities to complement internal growth and enhance its product portfolio[13]. Share Repurchase and Dividends - The company repurchased a total of 3,834,000 shares during the reporting period, at a total cost of HKD 32,897,016[87]. - The company did not declare or pay any dividends during the reporting period[75]. - The repurchase was aimed at enhancing net asset value per share and earnings per share, authorized by the board at the 2024 annual general meeting[88]. - As of June 30, 2025, all repurchased shares have been canceled[88]. Audit and Investigation - An independent forensic investigation is ongoing to address audit issues and assess their impact on business operations and financial condition[49]. - The company has engaged external consultants to review its internal control systems and procedures, with findings to be reported in early 2026[52].

香港交易及結算所有限公司及香港聯合交易所有限公司（「香港聯交所」）對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 百勝中國發佈 2025 年第四季度財務業績報告 ( 於美利堅合眾國特拉華州註冊成立的有限公司 ) （股份代號：9987） 2025年第四季度及全年財務業績公告 百勝中國控股有限公司（「本公司」）謹此發佈截至2025年12月31日止第四季度及全年的 的未經審核業績公告（「2025年第四季度及全年業績公告」）。本2025年第四季度及全年 業績公告可於香港聯交所網站www.hkexnews.hk及本公司網站http://ir.yumchina.com閱覽。 承董事會命 百勝中國控股有限公司 屈翠容 董事及首席執行官 Yum China Holdings, Inc. 百 勝 中 國 控 股 有 限 公 司 香港，2026年2月4日 於本公告日期，本公司董事會包括董事會主席及獨立董事胡祖六博士、執行董事屈翠容女士、非執行董事 Robert B. AIKEN 先生以及獨立董事 Mikel A. DU ...

Financial Performance - The company reported a revenue of $XX million for the fiscal year, representing a YY% increase compared to the previous year[2] - The company achieved a revenue of RMB 164.2 million for the year ended December 31, 2024, representing an 8.5% increase compared to 2023[15] - Net profit for the year reached RMB 45.0 million, reflecting a growth of RMB 15.0 million from the previous year[17] - Gross profit reached RMB 119.3 million, reflecting a 35.2% increase from RMB 88.3 million in the previous year, with a gross margin of 72.7%, up 14.3 percentage points[51] - Revenue from consumer-grade genetic testing services and related products was RMB 159.6 million, a significant increase of 47.3% from RMB 108.4 million in 2023[49] - Revenue from cancer screening services dropped to RMB 4.6 million, a decline of 89.2% from RMB 42.9 million in 2023 due to strategic adjustments[69] - The cash flow from operating activities for the reporting period was RMB 57.2 million, primarily due to the profit generated during the reporting year[87] - The cash and cash equivalents decreased by 5.4% from RMB 518.3 million as of December 31, 2023, to RMB 490.3 million as of December 31, 2024[88] User Growth and Market Expansion - User data showed an increase in active users to ZZ million, up by AA% year-over-year[2] - The company is expanding its market presence, targeting E new regions, which is expected to enhance overall market share by F%[156] - The company is focused on further developing the consumer-grade genetic testing market in China, with expectations of market penetration increasing from 0.8% in 2020 to 11.6% by 2030[54] - The company completed an acquisition of a strategic partner for $FF million, expected to enhance operational capabilities[2] - Market expansion efforts include entering the European market, targeting a market share of EE% within the next two years[2] Research and Development - The company is investing $DD million in R&D for new technologies aimed at enhancing product offerings[2] - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions[56] - The company has developed 114 commercialized testing solutions in consumer-grade genetic testing and cancer screening, with 94 of these being self-developed services[21] - The company is developing eight in vitro diagnostic (IVD) pipeline products, including three consumer-grade genetic testing products expected to receive medical device registration certificates by 2025[22] - Research and development investment amounted to RMB 19.2 million, a year-on-year decrease of 14.3%[61] Corporate Governance and Management - The company has a strong leadership team with diverse backgrounds in healthcare, finance, and management, enhancing its strategic planning and operational efficiency[142] - The board consists of seven members, including three executive directors, one non-executive director, and three independent non-executive directors[164] - The company has established a mechanism for assessing board independence, which is reviewed annually, ensuring strong independent judgment within the board[176] - The company is committed to maintaining strong investor relations and financial strategy planning under the leadership of its CFO[131] - The company has received annual written confirmations of independence from all independent non-executive directors, affirming their status as independent individuals[175] Sustainability and Social Responsibility - The management emphasized a commitment to sustainability, aiming for a reduction in carbon emissions by II% over the next five years[2] - The company aims to integrate ESG principles into its operations, focusing on social responsibility and improving service accessibility[18] - The company aims to deliver sustainable returns to shareholders while ensuring customer satisfaction through high-quality products and services[160] Strategic Planning and Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of BB%[2] - New product launches are expected to contribute an additional $CC million in revenue in the upcoming quarter[2] - The company plans to enhance its marketing budget by HH% to boost brand awareness and customer engagement[2] - The company is exploring selective geographic expansion and acquisition opportunities to complement internal growth and enhance its existing product portfolio[59] Audit and Compliance - The company is undergoing an independent forensic investigation regarding audit issues as part of the resumption guidance from the stock exchange[107] - An independent internal control review is being conducted to ensure compliance with listing rules and to assess the adequacy of internal controls[108] - The company has been suspended from trading on the Hong Kong Stock Exchange since April 1, 2025, pending compliance with resumption guidance[102] Diversity and Inclusion - The board consists of 7 directors, with 4 male and 3 female members, achieving a gender diversity target of at least 2 female directors[198] - The board's gender ratio is 42.9% female and 57.1% male, while the overall employee gender ratio is 58.5% female and 41.5% male[199] - The senior management team has a gender ratio of 30% female and 70% male, indicating a focus on gender diversity at higher levels[199] - The company has adopted measurable goals to enhance board diversity, including a commitment to gender diversity in senior management recruitment[200]

Financial Performance - The Group's revenue for the Reporting Period was approximately HK$13,420,000, representing an increase of approximately 8.5% compared to the Corresponding Period[12]. - The Group recorded a loss of approximately HK$5,089,000 for the Reporting Period, which is a decrease of approximately 44.3% compared to the Corresponding Period[12]. - Revenue for the six months ended November 30, 2025, increased to HK$13,420,000, up 8.5% from HK$12,368,000 in the same period of 2024[21]. - Loss before income tax improved to HK$4,845,000, a reduction of 46.9% from HK$9,141,000 in the prior year[21]. - Total comprehensive loss for the period was HK$5,089,000, down from HK$9,141,000, reflecting a 44.5% improvement[21]. - Basic and diluted loss per share decreased to HK(4.16) cents from HK(8.41) cents, indicating a 50.6% reduction in loss per share[21]. - The loss attributable to owners of the Company for the six months ended November 30, 2025, was HK$5,087,000, an improvement from a loss of HK$9,123,000 in the same period of 2024[62]. Assets and Liabilities - Non-current assets increased to HK$1,727,000 as of November 30, 2025, compared to HK$4,318,000 as of May 31, 2025[23]. - Current assets totaled HK$31,021,000, up from HK$27,281,000, representing a 13.4% increase[23]. - Current liabilities rose to HK$31,957,000 from HK$25,719,000, marking a 24.2% increase[24]. - Net assets decreased to HK$791,000 from HK$5,880,000, indicating a significant decline in equity[24]. - Total equity attributable to owners of the Company was HK$3,594,000, down from HK$8,681,000, reflecting a 58.6% decrease[24]. - The company has net current liabilities of approximately HK$936,000 as of 30 November 2025, indicating potential liquidity challenges[36]. Cash Flow and Financing - For the six months ended 30 November 2025, net cash used in operating activities was HK$469,000, a significant improvement from HK$8,465,000 in the same period of 2024[27]. - The company reported a net cash outflow from investing activities of HK$1,097,000, compared to a net inflow of HK$2,205,000 in the previous year[27]. - Financing activities generated net cash of HK$1,054,000, down from HK$6,160,000 in the previous year[27]. - The company had a net decrease in cash and cash equivalents of HK$512,000, compared to a decrease of HK$100,000 in the same period last year[27]. - Cash and cash equivalents at the end of the period were HK$1,037,000, down from HK$1,716,000 at the end of the previous period[27]. Operational Overview - The principal activities of the company are focused on the entertainment business in Hong Kong[43]. - Revenue from sales of tobacco, food, and beverage was HK$13,420,000, while entertainment income and event income were HK$0, indicating a shift in revenue sources[50]. - The Group operated 2 lounges during the reporting period, contributing to its entertainment and catering services[87]. Employee and Expenses - Employee benefits expenses decreased by approximately HK$2,863,000, or approximately 47.6%, from approximately HK$6,020,000 for the Corresponding Period to approximately HK$3,157,000 for the Reporting Period[101]. - Total depreciation decreased by approximately HK$855,000, or approximately 27.1%, from approximately HK$3,155,000 for the Corresponding Period to approximately HK$2,300,000 for the Reporting Period[102]. - Other expenses decreased by approximately HK$2,473,000, or approximately 58.8%, from approximately HK$4,206,000 for the Corresponding Period to approximately HK$1,733,000 for the Reporting Period[107]. Corporate Governance and Compliance - The Group's financial results for the reporting period complied with legal requirements and adequate disclosures were made[180]. - The Audit Committee reviewed the unaudited condensed consolidated financial statements and confirmed compliance with applicable accounting standards and GEM Listing Rules[180]. - The company has complied with the Corporate Governance Code throughout the reporting period, with some deviations noted[170]. Risks and Challenges - The company is exposed to significant risks due to fluctuations in the commercial real estate market, with substantial lease liabilities potentially affecting operations and financial stability[140]. - Purchases from the largest supplier accounted for over 60% of total purchases during the reporting period, with no long-term contract in place, posing a risk to operations if supply is interrupted[141]. Future Plans and Strategies - The company plans to implement measures to improve working capital and cash flows, including monitoring administrative expenses and operating costs[40]. - The Company continues to explore strategies for market expansion and potential new product development[175].

（於英屬處女群島註冊成立的有限公司） （股份代號： ） 年度報告 2025 2025 目 錄 | 公司資料 | 2 | | --- | --- | | 主席致辭 | 3 | | 管理層討論與分析 | 7 | | 董事及高級管理層的履歷詳情 | 19 | | 企業管治報告 | 24 | | 董事會報告 | 40 | | 環境、社會及管治報告 | 55 | | 獨立核數師報告 | 88 | | 綜合損益表 | 94 | | 綜合其他全面收益表 | 95 | | 綜合財務狀況表 | 96 | | 綜合權益變動表 | 98 | | 綜合現金流量表 | 100 | | 綜合財務報表附註 | 102 | | 五年間財務概要 | 194 | 公司資料 董事會 非執行董事 葉偉明先生 （主席） 林家禮博士 BBS JP 余俊傑先生 薪酬委員會 林家禮博士 BBS JP（主席） 葉偉明先生 余俊傑先生 提名及企業管治委員會 李林先生 （主席） 杜均先生（於二零二五年八月二十六日調任） 執行董事 翁曉奇先生 （首席執行官） （於二零二五年八月二十六日獲委任） 張麗女士 （首席財務官） 獨立非執行董事 葉偉明先生 林家禮博士 BB ...

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. 香港交易及結算所有限公司及香港聯合 交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲 明，並明確表示概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 INDIGO STAR HOLDINGS LIMITED 靛藍星控股有限 ...

於 本 公 告 中，「我 們」指 本 公 司 及（如 文 義 所 指）本 集 團。本 公 告 所 載 若 干 金 額 及 百 分比數字已作約整。如任何表格的總數與所列數額的總和有任何不符之處，皆為 約 整 所 致。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 本 公 司 刊 發 日 期 為2022年6月 10日的招股章程所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 截 至2024年12月31日止年度的 年度業績公告 美 因 基 因 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本集團」）截 至2024年12月31日 止 年 度（「報告期」）的 綜 合 業 績。 業務回顧及展望 業績回顧 概 覽 作為中國領先的基 ...

（於百慕達註冊成立的有限公司） （股份代號： 1332） 補充公告 茲提述透雲生物科技集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）於2025年4 月29日就本集團2024年年報（「2024年年報」）所作之公告。除文義另有所指外，本公告所 用詞彙與2024年年報所界定者具有相同涵義。本公司謹此提供以下補充資料，該等資料 應結合2024年年報一併閱讀。 有關投資政策及投資組合策略 Touyun Biotech Group Limited 透 雲 生 物 科 技 集 團 有 限 公 司 投資政策概要 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 投資組合行業集中及復甦展望 截至2024年12月31日，本集團的投資組合集中於金融服務業（包括證券交易、經紀業 務、放債及資產管理）。管理層對此策略重點的看法以及對該行業復甦的展望，基於以 下幾個相互關聯的因素。 管理層相信金融服務業提供具吸引力的經風險調整回報潛力，並有助於分散本集團的資 產基礎及風 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ORIENTAL UNIVERSITY CITY HOLDINGS (H.K.) LIMITED 東 方 大 學 城 控 股（ 香 港 ）有 限 公 司 （ 於 香 港 註 冊 成 立 的 有 限 公 司 ） （股份代號：8067） 中期業績公告 截至二零二五年十二月三十一日止六個月 聯交所GEM（「GEM」）的特色 GEM乃為較於聯交所上市的其他公司帶有更高投資風險的中小型公司提供上市的 市場。有意投資者應了解投資該等公司的潛在風險，並應僅於經過審慎周詳考慮後 方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主 板買賣的證券承受較大的市場波動風險，同時亦無法保證在GEM買賣的證券會有 一個高流通量的市場。 本公告乃遵照GEM證券上市規則（「GEM上市規則」）的規定提供有關東方大學城控 股（香港）有限公司（「本公司」）的資料，本公司董事（「董事」）願 ...

BOARD OF DIRECTORS Tian Cheng Holdings Limited 天成控股有限公司 （於開曼群島註冊成立的有限公司） (incorporated in the Cayman Islands with limited liability) Stock code 股份代號: 2110 INTERIM REPORT 中期報告 Tian Cheng Holdings Limited 天成控股有限公司 Contents 目錄 | | | Page | | --- | --- | --- | | | | 頁碼 | | Corporate Information | 公司資料 | 2 | | Management Discussion and Analysis | 管理層討論與分析 | 5 | | Condensed Consolidated Statement of Profit or Loss | 簡明綜合損益及 | 17 | | and Other Comprehensive Income | 其他全面收益表 | | | Condensed Consolidated Statement o ...